Frost & Sullivan, the growth partnership company, announced today that it will host a live, complimentary Growth Innovation Leadership (GIL) briefing titled, “Digital Therapeutics: Trends and Growth Opportunities” on Tuesday, June 26, 2018, from 11:00 AM to 12:00 PM Pacific Time.
The webinar will offer expert insight from Daniel Ruppar, Global Director of Digital Health, and Victor Camlek, Principal Analyst of Digital Health, both from the Transformational Health Practice at Frost & Sullivan.
For more information and to register for the webinar, please visit: http://frost.ly/2iz
“Digital therapeutics represents the synthesis of traditional bits and bytes and small and large molecules that will transform the patient experience,” explains Camlek. “Patients will benefit from new solutions aimed at behavior modification based on a combination of training, social networking and 24×7 patient guidance that should improve the potential that they will adhere to prescribed therapies or eliminate the need to rely solely on medication to manage chronic conditions.”
In addition, digital therapeutics presents a significant opportunity for traditional pharmaceutical therapeutics and information technology (IT) capabilities to converge over time to influence a new approach to increase positive patient outcomes while reducing the overall cost of healthcare.
WANT TO BUILD A FINANCIAL EMPIRE?
Subscribe to the Global Banking & Finance Review Newsletter for FREE Get Access to Exclusive Reports to Save Time & Money
By using this form you agree with the storage and handling of your data by this website. We Will Not Spam, Rent, or Sell Your Information.
“Digital therapeutics also appears as an advanced level of solutions from mHealth companies that will combine applications, patient education, professional intervention, and peer support that will increase patient engagement and medication adherence by augmenting or replacing traditional drug therapeutics,” notes Ruppar.
This timely webinar coincides with the U.S. Food and Drug Administration (FDA) PreCertification Program, described by the FDA as a “first-of-its-kind pilot program that will help revolutionize digital health regulation in the U.S.” The FDA wants to learn more about the methods utilized by software developers and digital health developers. This is an important milestone in the evolution of digital therapeutics observes Camlek.
The informative webinar will cover key insights:
Gain expert insight into the accurate definition of digital therapeutics and identify market participants;
Learn about new solutions from mHealth companies that will combine applications, patient education, professional intervention, and peer support to increase patient engagement and medication adherence by augmenting or replacing traditional drug therapeutics;
Hear opportunities to utilize digital therapeutics to improve medical workflow and patient communications; and